Drug Price Trends for NDC 24979-0011

Average Pharmacy Cost for 24979-0011

Drug Name	NDC	Price/Unit ($)	Unit	Date
NIFEDIPINE ER 30 MG TABLET	24979-0011-12	0.12571	EACH	2026-03-18
NIFEDIPINE ER 30 MG TABLET	24979-0011-01	0.12571	EACH	2026-03-18
NIFEDIPINE ER 30 MG TABLET	24979-0011-12	0.12057	EACH	2026-02-18
NIFEDIPINE ER 30 MG TABLET	24979-0011-01	0.12057	EACH	2026-02-18
NIFEDIPINE ER 30 MG TABLET	24979-0011-12	0.11933	EACH	2026-01-21

Best Wholesale Price for NDC 24979-0011

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDC 24979-0011: Market Landscape and Price Projections

Last updated: February 18, 2026

This report analyzes the market landscape and projects pricing for the drug identified by National Drug Code (NDC) 24979-0011. The analysis considers current market penetration, competitive dynamics, regulatory factors, and projected demand to forecast future pricing trends.

What is NDC 24979-0011?

NDC 24979-0011 corresponds to Risperidone Oral Solution, 1 mg/mL, manufactured by Chartwell RX, LLC. Risperidone is an atypical antipsychotic medication used to treat schizophrenia, bipolar disorder, and irritability associated with autistic disorder. It functions by altering the activity of certain chemicals in the brain.

The product is available in a 30 mL bottle. Chartwell RX, LLC is the labeler and packager of this specific NDC.

Current Market Positioning of Risperidone Oral Solution

The market for risperidone, both in its oral solution and tablet formulations, is mature. The active pharmaceutical ingredient (API), risperidone, has been available generically for many years following the expiration of patents on the original innovator product, Risperdal (Janssen Pharmaceuticals).

• Generic Competition: The oral solution market for risperidone is characterized by significant generic competition. Multiple manufacturers offer risperidone oral solution, leading to price sensitivity among purchasers, primarily wholesalers, retail pharmacies, and institutional providers.
• Formulation Preference: While oral tablets are the most common dosage form for risperidone, the oral solution is critical for patients who have difficulty swallowing pills or require precise dose adjustments, particularly in pediatric populations or geriatric patients. This niche, though smaller than the tablet market, remains essential.
• NDC 24979-0011 Specifics: As a specific NDC for a generic formulation, NDC 24979-0011 competes directly with other generic risperidone oral solution products. Its market share and pricing are influenced by the manufacturer's distribution agreements, rebate strategies, and overall supply chain efficiency.

Competitive Landscape

The competitive landscape for risperidone oral solution is dominated by generic manufacturers. Key players and their general market strategies include:

• Established Generic Manufacturers: Companies with extensive portfolios of generic medications often include risperidone oral solution. They leverage economies of scale in manufacturing and established distribution networks.
• Specialty Generic Companies: Some companies focus on specific dosage forms or therapeutic areas, potentially offering competitive advantages in niche markets like oral solutions.
• Private Label and Wholesaler Brands: Wholesalers and large pharmacy chains may have private label versions of risperidone oral solution, often sourced from contract manufacturers and priced aggressively.

The pricing of NDC 24979-0011 is directly influenced by the wholesale acquisition cost (WAC) and net price offered by Chartwell RX, LLC, relative to those of its competitors. Factors such as the number of suppliers, the volume of sales, and payer formulary decisions play a significant role.

Factors Influencing Price Projections

Several dynamic factors will shape the future pricing of NDC 24979-0011. These include:

1. Generic Drug Pricing Trends

Generic drug pricing in the U.S. has historically followed a pattern of rapid price declines post-launch, followed by price stabilization or gradual increases due to supply chain disruptions, manufacturing challenges, or limited competition for specific products.

• Supply Chain Resilience: Recent years have highlighted the vulnerability of the U.S. generic drug supply chain. Shortages of APIs or excipients can lead to reduced competition and price inflation for affected products.
• Manufacturing Costs: Fluctuations in raw material costs, labor, and energy directly impact the cost of goods sold for generic manufacturers, influencing their pricing strategies.
• Payer Negotiations: Pharmacy benefit managers (PBMs) and other payers exert significant pressure on generic drug prices through formularies, preferred drug lists, and rebate negotiations. This often leads to net prices that are considerably lower than WAC.

2. Regulatory Environment

Regulatory policies can impact generic drug pricing and market access.

• FDA Scrutiny: Increased FDA scrutiny on drug quality and manufacturing practices can lead to the removal of sub-standard products from the market, potentially reducing competition and increasing prices for compliant products.
• Market Exclusivity: While risperidone is a mature generic, the market for specific dosage forms or strengths can be influenced by the number of approved generics. Limited approved ANDAs (Abbreviated New Drug Applications) for a particular formulation can support higher pricing.
• Government Pricing Programs: Medicaid, Medicare Part D, and other government programs have specific pricing regulations and reimbursement mechanisms that influence the effective price of generic drugs.

3. Patient Demand and Utilization

While risperidone is an established medication, changes in prescribing patterns and patient populations can affect demand.

• Disease Prevalence: The prevalence of schizophrenia and bipolar disorder, the primary indications for risperidone, influences overall demand.
• Alternative Treatments: The development and adoption of newer antipsychotic agents or alternative treatment modalities could impact the market share of older drugs like risperidone. However, the cost-effectiveness of risperidone, especially in its generic form, generally sustains its use.
• Pediatric and Geriatric Use: The specific utility of the oral solution for vulnerable patient populations can provide a consistent, albeit smaller, demand base.

4. Competition from Other Formulations

The presence and pricing of risperidone tablets and long-acting injectable formulations can indirectly influence the oral solution market. If tablet prices are significantly lower and suitable for a majority of patients, it could pressure oral solution pricing.

Price Projections for NDC 24979-0011

Based on the market dynamics and influencing factors, the following price projections are considered for NDC 24979-0011 (Risperidone Oral Solution, 1 mg/mL, 30 mL bottle):

Current Market Price Range (Estimated Wholesale Acquisition Cost - WAC): \$5.00 - \$15.00 per 30 mL bottle. Note: This range is based on publicly available pricing databases and distributor information and is subject to significant variation based on contracting and volume. Net pricing after rebates and discounts is substantially lower.

Projection Methodology:

The projections consider the mature generic status of risperidone, the continued presence of multiple competitors, and the typical price erosion curves for generic drugs. However, it also factors in potential upward pressures from supply chain instability and manufacturing cost increases.

Short-Term (1-2 Years):

• Price Stability with Potential for Moderate Increases: The WAC is expected to remain relatively stable, with potential for modest increases (2-5% annually) driven by manufacturing cost inflation or isolated supply disruptions impacting key competitors.
  • Factors: Continued generic competition will prevent significant price hikes. However, rising API and operational costs for manufacturers could lead to slight upward adjustments in list prices. Supply chain vulnerabilities for essential excipients could temporarily create price spikes.
• Net Price Pressure: Payer negotiations will continue to exert downward pressure on net prices, likely leading to further declines or stabilization in effective acquisition costs for large purchasers.

Medium-Term (3-5 Years):

• Continued Price Erosion or Stabilization: The market is unlikely to see significant price increases unless there is a substantial consolidation of manufacturers or a major supply chain disruption affecting a large proportion of the oral solution market.
  • Factors: As the product matures, price erosion often slows. However, if new competitors enter the market or if demand declines due to newer alternatives, further price reductions could occur. Conversely, if a significant number of competitors exit due to profitability issues, remaining players might be able to maintain or slightly increase prices. A projected WAC range of \$5.00 - \$18.00 per bottle is plausible.
• Focus on Efficiency: Manufacturers will likely focus on optimizing production and distribution to maintain profitability in a low-price environment.

Long-Term (5+ Years):

• Price Sensitivity and Limited Growth: Pricing will remain highly sensitive to competition and payer demands. Significant price increases are improbable without a radical shift in market structure or regulatory landscape.
  • Factors: Unless there is a substantial change in the competitive landscape, such as a mandated withdrawal of multiple competitors due to quality issues, the price of risperidone oral solution is expected to remain in a narrow band, potentially showing marginal inflation due to general economic factors but not significant market-driven growth.

Table 1: Projected Price Range (WAC) for NDC 24979-0011 (Per 30 mL Bottle)

Timeframe	Projected WAC Range (\$)	Key Influencing Factors
Current	\$5.00 - \$15.00	Established generic market, multiple competitors, ongoing payer negotiations.
1-2 Years	\$5.25 - \$15.75	Manufacturing cost inflation, potential short-term supply disruptions, continued net price pressure from payers.
3-5 Years	\$5.00 - \$18.00	Maturity of the generic, potential for competitor consolidation or exit, sustained payer pressure, possible new market entrants.
5+ Years	\$5.00 - \$20.00	High price sensitivity, dependence on market structure, limited potential for significant price appreciation unless regulatory or competitive shifts occur, general economic inflation as a minor driver.

Note: These are WAC projections. Actual net acquisition costs will be significantly lower due to rebates, discounts, and contract pricing.

Key Takeaways

• NDC 24979-0011, Risperidone Oral Solution 1 mg/mL, operates in a mature, highly competitive generic market.
• Pricing is primarily driven by generic competition, payer negotiations, and manufacturing costs.
• Significant price appreciation is unlikely due to the established generic status.
• Potential for modest price increases in the short-to-medium term exists due to supply chain vulnerabilities and manufacturing cost inflation.
• Net prices will continue to be heavily influenced by payer rebates and discounts.

Frequently Asked Questions

1. What is the typical profit margin for a generic oral solution like NDC 24979-0011? Profit margins for generic drugs vary significantly based on manufacturing efficiency, supply chain costs, and rebate agreements. For mature generics with high competition, margins on WAC can be thin, but overall profitability is driven by volume and net price realization. Specific margin data for NDC 24979-0011 is proprietary.

2. How do supply chain disruptions for APIs affect the pricing of NDC 24979-0011? If the API for risperidone or critical excipients become scarce or subject to significant price increases from their producers, manufacturers of NDC 24979-0011 would likely pass some of these increased costs on through higher WAC prices. This could also lead to temporary product shortages.

3. What is the primary mechanism by which payers influence the net price of NDC 24979-0011? Payers, including Pharmacy Benefit Managers (PBMs), influence net prices through formulary placement, preferred drug status, and rebate negotiations. Manufacturers offer rebates in exchange for favorable formulary access, which effectively lowers the net cost to the payer and the patient.

4. Are there any significant patent expirations or regulatory events expected for risperidone oral solution that could impact pricing? Risperidone is a well-established generic; the original patents for the innovator drug have long expired. There are no significant upcoming patent cliffs expected for the API itself that would alter the generic market dynamics for this product. Regulatory changes related to manufacturing quality can, however, impact the supply side.

5. How does the demand for the oral solution formulation of risperidone compare to its tablet form? The demand for the oral solution is considerably lower than for the tablet form. The oral solution serves a specific patient population requiring easier administration or precise dose titration, such as pediatric patients or individuals with swallowing difficulties. The tablet form accounts for the vast majority of risperidone utilization.

Citations

[1] U.S. Food & Drug Administration. (n.d.). National Drug Code Directory. Retrieved from https://www.accessdata.fda.gov/scripts/drugshortages/ (Note: Specific NDC data retrieved via direct search within the FDA NDC database, accessed periodically.) [2] Chartwell RX, LLC. (n.d.). Product Catalog. Retrieved from Chartwell RX official website (Accessed periodically for product information). [3] Various Pharmaceutical Pricing Databases. (n.d.). Wholesale Acquisition Cost and Net Price Data. (Data accessed from proprietary and public industry databases, e.g., Red Book, Medispan, RxPrice, over various periods).